MoonLake CFO sells 87,795 shares under 10b5-1

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of Class A ordinary shares under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025 to cover his tax liabilities.

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of Class A ordinary shares under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025 to cover his tax liabilities.

He sold 85,870 shares on April 9, 2026 at a weighted average price of $18.94 per share and 1,925 shares on April 10, 2026 at a weighted average price of $19.51 per share, for total reported sales of 87,795 shares. Following these transactions, he directly holds 1,188,510 Class A ordinary shares.

Insider Trade Summary 10b5-1

Net Seller: 87,795 shares

Net Sell 2 txns

Insider Bodenstedt Matthias

Role Chief Financial Officer

Sold 87,795 shs ($1.66M)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	1,925	$19.51	$38K
Sale	Class A ordinary shares, par value $0.0001 per share	85,870	$18.94	$1.63M

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 1,188,510 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025 to cover tax liabilities of the Reporting Person.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.340 to $19.455. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. F3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.560. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold April 9, 2026: 85,870 shares at $18.94/share Shares sold April 10, 2026: 1,925 shares at $19.51/share Total shares sold: 87,795 shares +4 more

7 metrics

Shares sold April 9, 2026 85,870 shares at $18.94/share Open-market sale of Class A ordinary shares

Shares sold April 10, 2026 1,925 shares at $19.51/share Open-market sale of Class A ordinary shares

Total shares sold 87,795 shares Combined open-market sales reported in this Form 4

Shares held after transactions 1,188,510 shares Direct ownership of Class A ordinary shares following sales

Trading plan adoption date December 10, 2025 Rule 10b5-1 plan to cover tax liabilities

Price range April 9, 2026 $18.340–$19.455 Multiple sale executions; weighted average $18.94/share

Price range April 10, 2026 $19.500–$19.560 Multiple sale executions; weighted average $19.51/share

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A ordinary shares, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan financial

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action: "open-market sale" for these transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transactions did MoonLake Immunotherapeutics (MLTX) report for its CFO?

MoonLake Immunotherapeutics reported that CFO Matthias Bodenstedt sold a total of 87,795 Class A ordinary shares in two open-market transactions. These sales occurred on April 9 and April 10, 2026, as part of a pre-arranged Rule 10b5-1 trading plan to address personal tax liabilities.

At what prices did the MoonLake (MLTX) CFO sell his shares?

The CFO’s MoonLake share sales used weighted average prices. He sold 85,870 shares at $18.94 per share on April 9, 2026, and 1,925 shares at $19.51 per share on April 10, 2026. Each trade comprised multiple executions within disclosed price ranges.

How many MoonLake (MLTX) shares does the CFO hold after these sales?

After completing the reported transactions, CFO Matthias Bodenstedt directly holds 1,188,510 MoonLake Class A ordinary shares. This figure reflects his remaining position as reported in the Form 4, after selling a combined 87,795 shares across the two open-market transactions in April 2026.

Were the MoonLake (MLTX) CFO share sales made under a Rule 10b5-1 plan?

Yes. The filing states the CFO’s transactions were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. The plan was established specifically to cover his tax liabilities, indicating the sales were pre-planned rather than discretionary market-timing trades.

What price ranges applied to the MoonLake (MLTX) CFO’s share sales?

The filing notes weighted average prices with ranges. On April 9, 2026, sales occurred between $18.340 and $19.455 per share. On April 10, 2026, sales occurred between $19.500 and $19.560 per share. Detailed breakdowns are available on request from the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/10/2026 - 06:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenstedt Matthias

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	04/09/2026		S(1)		85,870	D	$18.94(2)	1,190,435	D
Class A ordinary shares, par value $0.0001 per share	04/10/2026		S(1)		1,925	D	$19.51(3)	1,188,510	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025 to cover tax liabilities of the Reporting Person.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.340 to $19.455. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.560. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)